Clinical trials recruiting for EGFR-TKI Resistant Mutation
4
Recruiting trials
0
US states with sites
2
Countries
0%
Accept healthy volunteers
Phase breakdown
Phase 1 1Phase 2 2Not applicable 2
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nintedanib, gefitinib, erlotinib, afatinib, osimertinib | 1 |
| Osimertinib plus Dalpiciclib | 1 |
Self-screener
Recruiting trials
- A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
- Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
- Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Related conditions
Trials recruiting for EGFR-TKI Resistant Mutation often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Non-small cell lung cancer 507EGFR Gene Mutation 11Lung Cancer, Non-small Cell 24EGFR Activating Mutation 6Circulating Tumor DNA 8
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for EGFR-TKI Resistant Mutation trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.